Works by Xiong, Jianping

Results: 121
    1
    2

    First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-025-02229-4
    By:
    • Shi, Yuankai;
    • Ba, Yi;
    • Wang, Junye;
    • Xiong, Jianping;
    • Gu, Kangsheng;
    • Chen, Yigui;
    • Zheng, Zhendong;
    • Wang, Zishu;
    • Guo, Weijian;
    • Cheng, Ying;
    • Yin, Xianli;
    • Liu, Yunpeng;
    • Bai, Yuxian;
    • Li, Enxiao;
    • Li, Qi;
    • Zhu, Liangjun;
    • Li, Wei;
    • Jiang, Da;
    • He, Jingdong;
    • Chen, Jiansi
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38

    Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.

    Published in:
    Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00886-2
    By:
    • Wang, Feng;
    • Qin, Shukui;
    • Sun, Xinchen;
    • Ren, Zhenggang;
    • Meng, Zhiqiang;
    • Chen, Zhendong;
    • Chai, Xiaoli;
    • Xiong, Jianping;
    • Bai, Yuxian;
    • Yang, Lin;
    • Zhu, Hong;
    • Fang, Weijia;
    • Lin, Xiaoyan;
    • Chen, Xiaoming;
    • Li, Enxiao;
    • Wang, Linna;
    • Yan, Ping;
    • Zou, Jianjun
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50